Jun. 22, 2017
Over the last 20 years, Singapore has successfully established a solid foundation for scientific innovation.
As part of a national strategy to become the Asian hub for biotechnology research and development, the multi-ethnic city-state actively promotes advanced clinical research, innovation, and enterprise. It also offers world-class intellectual property protection.
The Singapore government has established an integrated research ecosystem giving biotechnology companies easy access to multidisciplinary capabilities.
As a result, Singapore is now Asia's fastest growing bio-cluster. In 2015, 65% of the overall growth of manufacturing outputs were from Singapore's biotechnology sector alone.
Singapore's drive to establish itself as the Asian hub for biotechnology research and development has resulted in the creation of a multitude of research institutes.
Singapore established the Health Sciences Authority (HSA) as a statutory board of the Singapore Ministry of Health on April 1, 2001. The purpose: to provide an environment of innovation, ensure global standards of safety and quality and define new regulatory frameworks to pursue cutting-edge research in regulatory sciences.
Singapore's biomedical industry is considered to be the next driving force of the economy.
With its national strategy in full swing, both public and private sectors working together and research institutes proactively inviting top-level researchers from around the world, Singapore's biomedical industry is formidable.
With an outstanding infrastructural setup, Singapore is the ideal place for biotechnology research and clinical trials.